Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · IEX Real-Time Price · USD
1.740
-0.140 (-7.45%)
At close: Jul 2, 2024, 4:00 PM
1.750
+0.010 (0.57%)
After-hours: Jul 2, 2024, 7:51 PM EDT
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for AMLX stock have an average target of 5.20, with a low estimate of 3.00 and a high estimate of 8.00. The average target predicts an increase of 198.85% from the current stock price of 1.74.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AMLX stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 4 | 3 | 2 | 2 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 4 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +359.77% | Jun 24, 2024 |
| Mizuho | Mizuho | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +72.41% | May 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +359.77% | May 10, 2024 |
| Baird | Baird | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +72.41% | Apr 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +359.77% | Apr 11, 2024 |
Financial Forecast
Revenue This Year
99.10M
from 380.79M
Decreased by -73.98%
Revenue Next Year
338.42M
from 99.10M
Increased by 241.50%
EPS This Year
-2.92
from 0.70
EPS Next Year
-1.09
from -2.92
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 114.5M | 601.3M | 692.0M | 14.1M | 40.3M |
| Avg | 99.1M | 338.4M | 394.2M | 3.4M | 9.8M |
| Low | 86.8M | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -69.9% | 506.8% | 104.5% | -96.4% | 1,080.1% |
| Avg | -74.0% | 241.5% | 16.5% | -99.1% | 186.6% |
| Low | -77.2% | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.34 | 0.97 | 2.30 | -1.05 | -0.85 |
| Avg | -2.92 | -1.09 | -0.61 | -1.02 | -0.83 |
| Low | -3.97 | -2.00 | -1.86 | -0.98 | -0.79 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.